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OBJECTIVES The aim of this study was to investigate the relationship between circulating monocytes and
in-stent neointimal volume at six-month follow-up.
BACKGROUND In-stent neointimal hyperplasia is the main contributing factor to in-stent restenosis. There
is increasing evidence that white blood cells (WBCs), especially monocytes, play a central role
in restenosis after stent implantation.
METHODS We performed coronary stent implantation in 107 patients (107 lesions). Peripheral blood was
obtained from all patients immediately before coronary angiography and every day for seven
days after the intervention, and each WBC fraction count was analyzed. At scheduled
six-month follow-up, all patients received angiographic and volumetric intravascular ultra-
sound analysis.
RESULTS The circulating monocyte count increased and reached its peak two days after stent
implantation (from 350  167 to 515  149/mm3, p  0.01). The maximum monocyte
count after stent implantation showed a significant positive correlation with in-stent
neointimal volume at six-month follow-up (r  0.44, p  0.0001). Other fractions showed
neither significant serial changes nor a correlation with in-stent neointimal volume. Multiple
regression analysis revealed that in-stent neointimal volume was independently correlated
with stent volume immediately after implantation (r  0.45, p  0.0001) and maximum
monocyte count (r  0.35, p  0.001). Angiographic restenosis, defined as percent diameter
stenosis 50%, was observed in 22 patients (21%), and these patients showed a significantly
larger maximum monocyte count than patients without restenosis (642  110 vs. 529 
77/mm3, p  0.01).
CONCLUSIONS Circulating monocytes increased after coronary stent implantation, and the peak monocyte
count related to in-stent neointimal volume. Our results suggest that circulating monocytes
play a role in the process of in-stent neointimal hyperplasia. (J Am Coll Cardiol 2004;43:
18–23) © 2004 by the American College of Cardiology Foundation
Stent implantation for coronary artery disease is now estab-
lished as a therapeutic strategy of great benefit (1,2).
However, in-stent restenosis, which is a main limitation
of coronary stent implantation, remains unresolved (3).
See page 24
Excessive in-stent neointimal hyperplasia is the main con-
tributing factor to in-stent restenosis (4,5). There is in-
creasing evidence from several experimental studies that
white blood cells (WBCs), especially monocytes, play a
central role in restenosis after balloon angioplasty and stent
implantation (6–9). Previous studies have demonstrated
infiltration and accumulation of monocytes to the stenting
site, and these cells correlate with smooth muscle cell
(SMC) proliferation and neointimal growth (6,7). Also,
monocytes/macrophages have been demonstrated to be one
of the components of the neointima (9). However, there are
few studies that investigate the relationship between circu-
lating monocytes and in-stent neointima of human stented
lesions.
The aim of this study was to investigate the relationship
between circulating monocytes and in-stent neointimal
volume at six-month follow-up. We monitored the serial
changes in the monocyte count after stent implantation
and evaluated the relationship with in-stent neointimal
volume.
METHODS
Patient enrollment. Our patient population comprised 107
consecutive patients (107 lesions) who received successful
intravascular ultrasound (IVUS)-guided single-stent (stent
length 15 mm) implantation between May 2001 and March
2002 and returned for scheduled six-month follow-
up analysis. In this study, patients who met the following
criteria were excluded: 1) patients with a restenotic lesion
from a previous intervention; 2) patients requiring multiple
stenting in one lesion; 3) patients having a culprit lesion with
an arc of calcification 90°; and 4) patients with a left main
coronary artery lesion or chronic total occlusion lesion.
To examine the effect of coronary angiography itself on
each WBC fraction count, we selected 131 patients who
underwent coronary angiography but had no intervention in
the same period as a non-intervention group.
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Protocol for intervention and follow-up. Coronary an-
giography was performed using a standard technique (10).
All patients initially received a bolus injection of 10,000 IU
heparin and intracoronary isosorbide dinitrate (5 mg)
before angiography. After completion of the diagnostic
coronary angiogram, pre-intervention IVUS was per-
formed using a 0.014-inch (0.035-cm) guide wire. The
IVUS catheter (3.2F; Ultra Cross, Boston Scientific
Scimed, Inc., Maple Grove, Minnesota) was carefully ad-
vanced distal to the lesion under fluoroscopic guidance. It
was then pulled back automatically from the distal portion
at 0.5 mm/s to the culprit lesion, and the vessel diameter
(media to media) was measured. All IVUS images were
recorded on S-VHS videotape for off-line analysis. After
IVUS evaluation, balloon pre-dilation and primary stenting
were performed using a Multi-Link stent (ACS, Santa
Clara, California) sized to 90% of the media-to-media
diameter on IVUS and dilated at 14 atm. After stent
implantation, a non-compliant balloon, sized in the same
way, was used for post-dilation at 10 atm, with the
inflation pressure increased until the minimum lumen area
of the stented site was 80% of the distal reference
cross-sectional area (CSA) on IVUS. All patients were
started on a post-procedural regimen of 81 mg/day aspirin
and 200 mg/day ticlopidine hydrochloride.
At scheduled six-month follow-up, patients received a
bolus injection of 3,000 IU heparin and 5 mg intracoronary
isosorbide dinitrate, with coronary angiography and volu-
metric IVUS analysis using the same protocol. The protocol
for the study was approved by the Ethics Committee of
Osaka City University Hospital. We obtained written,
informed consent from all participants before coronary
angiography and stent implantation.
Measurement of WBC count. Peripheral blood was ob-
tained from all patients immediately before coronary an-
giography and every day for seven days after the procedure.
Blood sampling was performed carefully and gently to avoid
Table 1. Patient Characteristics and Angiographic Results
No. of patients (lesions) 107 (107)
Age (yrs) 63.8  9.2
Male/female 82 (77%)/25 (23%)
Hypertension 51 (48%)
Diabetes mellitus 31 (29%)
Hypercholesterolemia (220 mg/dl) 47 (44%)
Smoking 46 (43%)
Reference diameter (mm) 3.0  0.3
Minimum lumen diameter (mm) 0.5  0.4
Diameter stenosis (%) 83.4  14.0
Stent size (mm) 3.5  0.3
Maximum inflation pressure (atm) 12.2  1.4
Final reference diameter (mm) 3.3  0.3
Final minimum lumen diameter (mm) 2.9  0.4
Final diameter stenosis (%) 11.6  6.1
Data are presented as mean  SD or number (%) of patients.
Figure 1. Serial changes in each white blood cell (WBC) fraction count after stent implantation were demonstrated. Monocytes increased after stent
implantation and reached a peak level two days after the procedure (from 350  167 to 515  149/mm3, p  0.01). Other fractions had no significant
serial change.
Abbreviations and Acronyms
CSA  cross-sectional area
EEM  external elastic membrane
IVUS  intravascular ultrasound
SMC  smooth muscle cell
WBC  white blood cell
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hemolysis. Total WBCs and each fraction count were
measured with an automated hematology analyzer (XE-
2100, Sysmex, Kobe, Japan). Measurements of WBC count
were also made using the same protocol for patients in the
non-intervention group.
Angiographic analysis. Coronary angiograms were re-
viewed separately by two independent observers unaware of
the IVUS findings and clinical data (Drs. Shimada and
Yoshiyama). Quantitative angiography was performed off-
line using the CMS-QCA system (CMS-MEDIS, Medical
Imaging Systems, Leiden, The Netherlands). Reference
diameter, minimum lumen diameter, and percent diameter
stenosis at the end-diastolic phase were calculated. Angio-
graphic restenosis was defined as percent diameter stenosis
50% at follow-up.
Volumetric IVUS analysis. Videotaped IVUS images
were analyzed by two experienced observers (Drs. Tanaka
and Kawarabayashi) blinded to the angiograms and clinical
results. Measurements of the external elastic membrane
(EEM) CSA, stent area, and lumen area were made every
2 s of videotape, using a computer-associated algorithm
(TapeMeasure, Indec Systems, Capitola, California).
Therefore, in effect, each stent was axially divided into
several 1-mm segments. Volumetric measurement of the
stented segment was made by applying Simpson’s rule.
Neointimal volume was defined as the difference between
stent volume and lumen volume. The reproducibility of
IVUS measurements of EEM, stent area, and lumen area
has already been reported. In no patient was visualization of
the EEM in stented segments hampered by the stent
filaments.
Statistical analysis. Data are expressed as the mean value
 SD. Serial changes in each WBC fraction count were
evaluated by two-way analysis of variance with repeated
measures using the Scheffe´ F test. The strength of the
association of each WBC fraction count with in-stent
neointimal volume was assessed by linear regression analy-
sis. Multiple regression analysis was performed for several
parameters (i.e., male gender, age, classic coronary risk
factors, stent volume immediately after stent implantation,
and maximum monocyte count), predicting the in-stent
neointimal volume. A p value 0.05 was considered statis-
tically significant.
RESULTS
Patient characteristics. Baseline patient characteristics
are shown in Table 1. In our study population, there was
Figure 2. Comparison of maximum monocyte counts. Patients with
restenosis showed a significantly larger maximum monocyte count than did
patients without restenosis (642  110 vs. 529  77/mm3, p  0.001).
Figure 3. Serial changes in each white blood cell (WBC) fraction count in the non-intervention group were demonstrated. Unlike patients who underwent
stent implantation, there were no significant serial changes in each WBC fraction count, including monocytes, in the non-intervention group.
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no in-hospital death or subacute stent thrombosis, and
during the follow-up period, there were also no major
adverse cardiac events. Follow-up angiography and IVUS
evaluation were performed at 6.5  1.1 months in all
patients (107 lesions). At follow-up, angiographic in-stent
restenosis was observed in 22 patients (21%).
Peripheral monocyte count. The serial changes in each
WBC fraction count are shown in Figure 1. The monocyte
count increased after stent implantation and reached its
peak two days after the procedure (from 350  167 to
515  149/mm3, p  0.01). However, other fractions had
no significant change. Also, patients with restenosis showed
a significantly larger maximum monocyte count than did
patients without restenosis (642  110 vs. 529  77/mm3,
p  0.001), as shown in Figure 2. Patients in the non-
intervention group showed no significant serial changes in
each WBC fraction count, including monocytes, as shown
in Figure 3.
Relationship between monocyte count and in-stent neo-
intimal volume. The maximum monocyte count after stent
implantation showed a significant positive correlation with
in-stent neointimal volume at six-month follow-up (r 
0.44, p  0.0001), as shown in Figure 4. However, other
fractions had no correlation with in-stent neointimal vol-
ume. Multiple regression analysis revealed that in-stent
neointimal volume was independently correlated with stent
volume immediately after stent implantation (r  0.45, p 
0.0001) and maximum monocyte count (r  0.35, p 
0.001), as shown in Table 2.
Figure 5 shows typical cases of patients with restenosis
(part A) and without restenosis (part B). Both of these
patients underwent stent implantation in the mid right
coronary artery portion using a 3.5-mm Multi-Link stent
(stent length 15 mm). One patient (Fig. 5A) presented with
76.12 mm3 of in-stent neointima and 621/mm3 maximum
monocyte count, whereas another patient (Fig. 5B) had
27.9 mm3 of in-stent neointima and 259/mm3 maximum
monocyte count.





Age (yrs) 0.052 0.572
Male 0.003 0.977
Hypertension 0.009 0.919
Diabetes mellitus 0.074 0.41
Hypercholesterolemia 0.122 0.171
Stent volume immediately after
implantation
0.423  0.0001
Maximum monocyte count (/mm3) 0.324 0.0007
Figure 4. The relationship between the maximum count of each white blood cell (WBC) fraction and in-stent neointimal volume after six-month follow-up
was demonstrated. The maximum monocyte count showed a significant positive correlation with in-stent neointimal volume (r  0.44, p  0.0001). Other
fractions had no significant correlation with in-stent neointimal volume.
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DISCUSSION
Previously, the important role of WBCs, especially
monocytes, in in-stent neointimal proliferation has been
demonstrated, although no study has revealed the rela-
tionship between in-stent neointima and circulating
monocytes. We showed the positive correlation between
circulating monocytes and in-stent neointimal volume in hu-
man stented lesions. The SMCs are known to be the major
cellular component of in-stent neointima. Excessive accu-
mulation of SMCs has a key role in in-stent neointimal
hyperplasia; however, the origin of SMCs is still not well
established.
Neointimal SMCs were thought to originate locally
from the SMCs of the medial layer in the vascular injury
models and graft vasculopathy models (11,12). Adherent
activated monocytes/macrophages secrete numerous
growth factors, cytokines, and metalloproteinases and pro-
mote the migration and proliferation of SMCs to the
subendothelial space (13–15). Our results may reflect the
monocyte-related migration and proliferation of SMCs and
neointimal growth.
The advance of stem-cell science has revealed that bone
marrow contains multipotent adult stem cells with a high
capacity for differentiation (16–20). The peripheral mono-
cyte fraction, as we focused on in this study, is known to
include bone marrow stem cells (21,22). Previous reports
have demonstrated that neointimal lesions in graft vascu-
lopathy models were formed by the attachment and pro-
liferation of recipient circulating SMC progenitor cells, and
these reports have also demonstrated that bone marrow
cells contribute to neointimal lesions in vascular injury
models (23,24). Also, other reports have demonstrated that
circulating endothelial progenitor cells derived from bone
marrow incorporate into re-endothelialization after vascular
injury (25,26). A more recent study has reported the out-
growth of SMCs from peripheral circulating mononuclear cells
(27). Our results suggest a possible mechanism by which
increased monocytes, including progenitor cells, derived from
bone marrow, differentiate to the neointimal SMCs and
contribute to neointimal formation in human stented
lesions.
The origin of SMCs is still controversial, and further
Figure 5. Typical examples of patients with restenosis (A) and without restenosis (B). Both of these patients underwent stent implantation in the mid right
coronary artery portion using a 3.5-mm Multi-Link stent (15 mm in length) (arrows). The patient with restenosis presented with 76.12 mm3 of in-stent
neointima and 621/mm3 maximum monocyte count, whereas the patient without restenosis had 27.9 mm3 of in-stent neointima and 259/mm3 maximum
monocyte count.
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studies are needed. In either case, circulating monocytes
may play an important role in the process of neointimal
proliferation after stent implantation in humans.
Study limitations. Our study has several limitations. We
did not investigate membrane antigen of monocytes, so the
exact origin of increasing monocytes after stent implanta-
tion was unclear. In addition, functional analysis of mono-
cytes was not performed. Finally, to analyze each WBC
fraction count, we only performed automated measurements
in this study.
Clinical implication. Our results suggest that circulating
monocytes relate to the process of in-stent neointimal
hyperplasia in human stented lesions. This proposes a new
point of view of mechanisms of in-stent restenosis and
suggests a new therapeutic target.
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